Pharmacy Market BUZZ

Market News, Products, Services, and Trends

Severe Asthma Management: Addressing Emerging Evidence Regarding Phenotypes and Biomarkers


TARGET AUDIENCE

This activity has been developed for the pharmacist engaged in the care of patients with severe asthma. Other members of the care team may also participate.


EDUCATIONAL OBJECTIVES

After participating in this educational activity, learners should be better able to:

1. Review the current state of severe asthma management, including emerging evidence regarding phenotypes and biomarkers, as well as mechanisms of action of approved and upcoming biologic therapies

2. Analyze the role of the pharmacist in severe asthma management and barriers to achieving optimal asthma control in the pharmacy setting

3. Evaluate strategies to increase both medication adherence and patient confidence in pharmacists as asthma management specialists

4. Address the current issues and challenges for managed care in the treatment of severe asthma and formulate an action plan to alleviate these burdens


CLINICAL NEED

Asthma is a common respiratory disease in both adults and children. Severe or uncontrolled asthma significantly impacts a person’s health and quality of life. As the processes that drive asthma are better understood and targeted therapies are developed, patients with severe asthma have more options. When treatment is selected based upon patient-specific factors that can influence efficacy, clinical benefits and outcomes can be optimized.


As part of the interprofessional severe asthma healthcare team, pharmacists play a key role in educating their colleagues about new and emerging treatments for severe uncontrolled asthma and implications for patient care.


Today's Posts
Subscribe